A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Completed · Phase 2 · Has a placebo group

Conditions studied: Opioid-induced Constipation (OIC)

In brief

A dose-escalation study to assess the safety, tolerability and clinical activity of TD-1211 in patients with opioid-induced constipation.

Key facts

Study ID

NCT01333540

Run by

Glycyx Therapeutics

People needed

69

Starts

2011-05-01

Expected to finish

2012-06-01

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females between 18 and 65 years of age, inclusive
• Subjects with documented OIC on stable opioid regimen
• Willingness to stop all laxatives throughout run-in and treatment period

You may not qualify if…

• Any clinically significant findings in subjects with OIC
• Have participated in another clinical trial of an investigational drug 30 days prior to screening
• History of chronic constipation prior to opioid therapy in OIC subjects
• Active medical disorders associated with diarrhea or intermittent loose stools in OIC subjects

Where it is running

• Clinical Research Unit — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.